Document is current

Article History

Received: 15 December 2017

Accepted: 1 August 2018

First Online: 21 August 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: This study had been approved by the local ethical review board (Ethikkommission der Ärztekammer des Saarlandes—No. 178/17). All procedures performed in this study were in accordance with the ethical standards of this institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.

: The Burkitt lymphoma cell line DAUDI was acquired on March 18, 2015 from the “Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures” (Braunschweig, Germany, Invoice 01502841-1) and the breast cancer cell line ZR-75-1 was acquired on May 07, 2014 from “CLS-Cell Lines Service Ltd.” (Eppelheim, Germany, Invoice R140381). Both providers guarantee the authenticity of the respective cell line. Thus, at the time of the study, the two cell lines were not older than 2 years and were used only in our laboratory. During the study, the authenticity of the lines was ensured by the fact that the antibodies used to induce the ADCC always functioned cell-line-specifically. Moreover, these cell lines are also not included in the list of confirmed misidentified and cross-contaminated cell lines.